March 23, 2021 -- Thermo Fisher Scientific announced that it plans to collaborate with Protein Metrics on mass spectrometry data analysis for biopharmaceutical and proteomics applications. The company also launched its new Gibco human plasma-like medium for more physiologically relevant cell culture models.
The nonexclusive comarketing agreement will integrate Thermo Fisher's Chromeleon Chromatography Data System (CDS) with Protein Metrics Byos platform for protein characterization and its Byosphere enterprise platform -- the latter of which allows for automation, collaboration, and data management for good practice (GxP) and non-GxP environments.
The Byos platform enables researchers to move from raw data files to reporting in just minutes, allowing efficient and speedy monitoring of post-translational modifications and other critical quality attributes.
Separately, Thermo Fisher announced the launch of its new Gibco human plasma-like medium (HPLM). The cell culture medium is the first on the market to mimic the metabolic profile of human plasma and is designed to provide researchers with a realistic view of cell growth within the human body.
The media contains the same salt concentrations found in human plasma, as well as the same concentrations of over 60 polar metabolites, such as amino acids, nucleic acids, sugars, and small organic acids. The company noted that for most cell lines, adaptation is not required to transition from conventional medium to HPLM.